Implementing Treatment of Opioid-Use Disorder in Rural Settings: a Focus on HIV and Hepatitis C Prevention and Treatment

Overview

Journal Curr HIV/AIDS Rep

Publisher Current Science

Specialty Infectious Diseases

Date 2018 Jun 28

PMID 29948609

Citations 16

Authors

Jennifer R Havens

Sharon L Walsh

P Todd Korthuis

David A Fiellin

Affiliations

Soon will be listed here.

Abstract

Purpose Of Review: To describe the epidemiology of opioid-use disorder in the rural United States (U.S.) as it pertains to HIV and hepatitis C transmission and treatment resources.

Recent Findings: Heroin and fentanyl analogs have surpassed prescription opioids in their availability in rural opioid markets adding to HIV and hepatitis C (HCV) and overdose risks. Only 18% of rural individuals live in towns with inpatient services which are of limited quality and utility. Opioid treatment programs that provide methadone are not located in rural areas and only 3% of the primary care providers have the ability to prescribe buprenorphine. National models and resources have been established but lack implementation in rural areas leading to ongoing HIV and HCV transmission and overdose. Addressing the adverse impact of opioids in the rural U.S. will require a concerted effort to implement effective treatments according to national standards.

Citing Articles

The synthetic opioid fentanyl increases HIV replication in macrophages.

Madhuravasal Krishnan J, Kong L, Meeds H, Roskin K, Medvedovic M, Sherman K PLoS One. 2025; 20(2):e0298341.

PMID: 40014575 PMC: 11867328. DOI: 10.1371/journal.pone.0298341.

Peer-assisted telemedicine hepatitis-C treatment for people who use drugs in rural communities: a mixed methods study.

Hoffman K, Leichtling G, Shin S, Seaman A, Gailey T, Spencer H Addict Sci Clin Pract. 2025; 20(1):10.

PMID: 39923115 PMC: 11806898. DOI: 10.1186/s13722-025-00541-6.

Harm Reduction in Peer-Assisted Telemedicine for Hepatitis C: Secondary Outcomes of a Randomized Controlled Trial.

Spencer H, Gregoire D, Leichtling G, Herink M, Seaman A, Korthuis P Viruses. 2024; 16(9).

PMID: 39339931 PMC: 11437492. DOI: 10.3390/v16091455.

Supporting direct acting antiviral medication adherence and treatment completion in a sample of predominantly rural veterans with hepatitis C and substance use disorders.

Burton M, Voluse A, Patel A Addict Sci Clin Pract. 2024; 19(1):51.

PMID: 38918869 PMC: 11197191. DOI: 10.1186/s13722-024-00480-8.

A Scoping Review of Opioid Use Disorder Treatment Barriers and Telehealth for African Americans with Disabilities in Rural Communities.

McCray S, Ward-Sutton C, Moore C, Ole Koissaba B, Starr R, Manyibe E J Rehabil. 2024; 88(1):74-87.

PMID: 38528879 PMC: 10961997.

References

Fiellin D, Pantalon M, Pakes J, OConnor P, Chawarski M, Schottenfeld R . Treatment of heroin dependence with buprenorphine in primary care. Am J Drug Alcohol Abuse. 2002; 28(2):231-41. DOI: 10.1081/ada-120002972. View

Katz D, Hays L . Adolescent OxyContin Abuse. J Am Acad Child Adolesc Psychiatry. 2004; 43(2):231-4. DOI: 10.1097/00004583-200402000-00020. View

Compton W, Volkow N . Major increases in opioid analgesic abuse in the United States: concerns and strategies. Drug Alcohol Depend. 2005; 81(2):103-7. DOI: 10.1016/j.drugalcdep.2005.05.009. View

Compton W, Volkow N . Abuse of prescription drugs and the risk of addiction. Drug Alcohol Depend. 2006; 83 Suppl 1:S4-7. DOI: 10.1016/j.drugalcdep.2005.10.020. View

Fiellin D, Pantalon M, Chawarski M, Moore B, Sullivan L, OConnor P . Counseling plus buprenorphine-naloxone maintenance therapy for opioid dependence. N Engl J Med. 2006; 355(4):365-74. DOI: 10.1056/NEJMoa055255. View

Havens J, Walker R, Leukefeld C . Prevalence of opioid analgesic injection among rural nonmedical opioid analgesic users. Drug Alcohol Depend. 2006; 87(1):98-102. DOI: 10.1016/j.drugalcdep.2006.07.008. View

Sullivan L, Barry D, Moore B, Chawarski M, Tetrault J, Pantalon M . A trial of integrated buprenorphine/naloxone and HIV clinical care. Clin Infect Dis. 2006; 43 Suppl 4:S184-90. DOI: 10.1086/508182. View

Alford D, Labelle C, Richardson J, OConnell J, Hohl C, Cheng D . Treating homeless opioid dependent patients with buprenorphine in an office-based setting. J Gen Intern Med. 2007; 22(2):171-6. PMC: 1824722. DOI: 10.1007/s11606-006-0023-1. View

Sullivan L, Moore B, Chawarski M, Pantalon M, Barry D, OConnor P . Buprenorphine/naloxone treatment in primary care is associated with decreased human immunodeficiency virus risk behaviors. J Subst Abuse Treat. 2007; 35(1):87-92. PMC: 2587397. DOI: 10.1016/j.jsat.2007.08.004. View

10.

Fiellin D, Moore B, Sullivan L, Becker W, Pantalon M, Chawarski M . Long-term treatment with buprenorphine/naloxone in primary care: results at 2-5 years. Am J Addict. 2008; 17(2):116-20. DOI: 10.1080/10550490701860971. View

11.

Wood E, Kerr T, Marshall B, Li K, Zhang R, Hogg R . Longitudinal community plasma HIV-1 RNA concentrations and incidence of HIV-1 among injecting drug users: prospective cohort study. BMJ. 2009; 338:b1649. PMC: 2675696. DOI: 10.1136/bmj.b1649. View

12.

Hays L, Kirsh K, Passik S . Seeking drug treatment for OxyContin abuse: a chart review of consecutive admissions to a substance abuse treatment facility in Kentucky. J Natl Compr Canc Netw. 2009; 1(3):423-8. DOI: 10.6004/jnccn.2003.0035. View

13.

Lucas G, Chaudhry A, Hsu J, Woodson T, Lau B, Olsen Y . Clinic-based treatment of opioid-dependent HIV-infected patients versus referral to an opioid treatment program: A randomized trial. Ann Intern Med. 2010; 152(11):704-11. PMC: 2886293. DOI: 10.7326/0003-4819-152-11-201006010-00003. View

14.

Arora S, Kalishman S, Thornton K, Dion D, Murata G, Deming P . Expanding access to hepatitis C virus treatment--Extension for Community Healthcare Outcomes (ECHO) project: disruptive innovation in specialty care. Hepatology. 2010; 52(3):1124-33. PMC: 3795614. DOI: 10.1002/hep.23802. View

15.

Montaner J, Lima V, Barrios R, Yip B, Wood E, Kerr T . Association of highly active antiretroviral therapy coverage, population viral load, and yearly new HIV diagnoses in British Columbia, Canada: a population-based study. Lancet. 2010; 376(9740):532-9. PMC: 2996043. DOI: 10.1016/S0140-6736(10)60936-1. View

16.

Young A, Havens J, Leukefeld C . Route of administration for illicit prescription opioids: a comparison of rural and urban drug users. Harm Reduct J. 2010; 7:24. PMC: 2967505. DOI: 10.1186/1477-7517-7-24. View

17.

Altice F, Bruce R, Lucas G, Lum P, Korthuis P, Flanigan T . HIV treatment outcomes among HIV-infected, opioid-dependent patients receiving buprenorphine/naloxone treatment within HIV clinical care settings: results from a multisite study. J Acquir Immune Defic Syndr. 2011; 56 Suppl 1:S22-32. PMC: 3263431. DOI: 10.1097/QAI.0b013e318209751e. View

18.

Fiellin D, Weiss L, Botsko M, Egan J, Altice F, Bazerman L . Drug treatment outcomes among HIV-infected opioid-dependent patients receiving buprenorphine/naloxone. J Acquir Immune Defic Syndr. 2011; 56 Suppl 1:S33-8. PMC: 3863630. DOI: 10.1097/QAI.0b013e3182097537. View

19.

Korthuis P, Tozzi M, Nandi V, Fiellin D, Weiss L, Egan J . Improved quality of life for opioid-dependent patients receiving buprenorphine treatment in HIV clinics. J Acquir Immune Defic Syndr. 2011; 56 Suppl 1:S39-45. PMC: 3073082. DOI: 10.1097/QAI.0b013e318209754c. View

20.

Weiss L, Netherland J, Egan J, Flanigan T, Fiellin D, Finkelstein R . Integration of buprenorphine/naloxone treatment into HIV clinical care: lessons from the BHIVES collaborative. J Acquir Immune Defic Syndr. 2011; 56 Suppl 1:S68-75. DOI: 10.1097/QAI.0b013e31820a8226. View